These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23506557)

  • 1. Circulating endothelial cell levels in psoriatic patients and their modification after an anti-TNF-alpha (Etanercept) treatment.
    De Simone C; Caldarola G; Coco V; Palumbo S; Pocino K; Sgambato A; Maiorino A; Corbi M; Sandri MT; Vendittelli F; Capoluongo E
    J Eur Acad Dermatol Venereol; 2014 May; 28(5):590-6. PubMed ID: 23506557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
    Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
    Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased number of circulating endothelial cells (CECs) in patients with psoriasis--preliminary report.
    Batycka-Baran A; Paprocka M; Krawczenko A; Duś D; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2014 Jan; 28(1):116-9. PubMed ID: 22882471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
    Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
    Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Videocapillaroscopic findings in the microcirculation of the psoriatic plaque during etanercept therapy.
    Stinco G; Buligan C; Maione V; Valent F; Patrone P
    Clin Exp Dermatol; 2013 Aug; 38(6):633-7. PubMed ID: 23763515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
    Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis.
    Piaserico S; Sandini E; Saldan A; Abate D
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S73-6. PubMed ID: 25381985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
    Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
    J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
    Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
    Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
    Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study.
    Boehncke S; Salgo R; Garbaraviciene J; Beschmann H; Hardt K; Diehl S; Fichtlscherer S; Thaçi D; Boehncke WH
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1187-93. PubMed ID: 21241371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment.
    Cordiali-Fei P; Ardigò M; Mastroianni A; Giuliani A; D' Agosto G; Bordignon V; Trento E; Vento A; Berardesca E
    Int J Immunopathol Pharmacol; 2008; 21(3):643-9. PubMed ID: 18831932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.
    Bacchetti T; Campanati A; Ferretti G; Simonetti O; Liberati G; Offidani AM
    Br J Dermatol; 2013 May; 168(5):984-9. PubMed ID: 23614561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.